Log in

Relevant bibliographies by topics / Myelosuppression

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Myelosuppression'

Author: Grafiati

Published: 4 June 2021

Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Myelosuppression.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Myelosuppression"

1

Miller, Rickey C., and Alison Steinbach. "Growth Factor Use in Medication-Induced Hematologic Toxicity." Journal of Pharmacy Practice 27, no. 5 (September 23, 2014): 453–60. http://dx.doi.org/10.1177/0897190014546113.

Full text

Abstract:

Myelosuppression is a dose-limiting adverse effect with antineoplastic therapy and nonchemotherapy medications. Clinicians have data and guidelines to provide direction for the management of neutropenia and thrombocytopenia in patients with malignancies. Clinical situations outside oncology extrapolate these data along with limited data sets for those patients who demonstrate myelosuppressive effects from medications that are not traditionally considered cytotoxic. Pharmacological treatments can be used to help ameliorate the myelosuppressive toxicities. Recombinant technology has provided growth factors to counteract or lessen the degree of toxicity from myelosuppressive medications including chemotherapy. Clinical strategies and future trends on how to mitigate medication-related myelosuppression are discussed.

APA, Harvard, Vancouver, ISO, and other styles

2

Smith, Robert E. "Trends in Recommendations for Myelosuppressive Chemotherapy for the Treatment of Solid Tumors." Journal of the National Comprehensive Cancer Network 4, no. 7 (August 2006): 649–58. http://dx.doi.org/10.6004/jnccn.2006.0056.

Full text

Abstract:

Lung, breast, and colorectal cancers are the 3 most frequent causes of cancer-related death in the United States. In the past 15 years, survival has increased dramatically for patients with these tumor types, partly because improved chemotherapy caused major changes in standard care. In addition, maintaining chemotherapy dose intensity has an established a positive effect on patient outcomes. However, delivering chemotherapy at full dose and on schedule is limited primarily by myelosuppression. To determine how expert opinion about preferred chemotherapy for lung, breast, and colorectal cancers has changed over the past decade, the National Comprehensive Cancer Network (NCCN) treatment guidelines from 1996, 2000 or 2001, and 2005 for each tumor type were compared. The myelosuppressive potentials of NCCN-recommended agents were assessed using data from their prescribing information. Many agents and combinations of agents recommended in the NCCN guidelines for treating lung, breast, and colorectal cancers are associated with myelosuppression. Several of these myelosuppressive regimens, which were previously recommended for treating advanced-stage or metastatic disease, are now preferred for early-stage disease, and neoadjuvant or adjuvant therapy is now recommended in more tumor types and stages than ever before. These findings indicate that the cytotoxic agents and regimens recommended today are associated with more myelosuppression than those preferred a decade ago and are more widely used in early-stage disease when survival benefits are possible. Because of this trend toward more intensive treatment of patients with cancer, proactive steps should be taken to minimize the risk for myelosuppression and its complications while optimizing the relative dose intensity.

APA, Harvard, Vancouver, ISO, and other styles

3

Carey, Peter J. "Drug-Induced Myelosuppression." Drug Safety 26, no. 10 (2003): 691–706. http://dx.doi.org/10.2165/00002018-200326100-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Randolph-Habecker, Julie, Mineo Iwata, and Beverly Torok-Storb. "Cytomegalovirus mediated myelosuppression." Journal of Clinical Virology 25 (August 2002): 51–56. http://dx.doi.org/10.1016/s1386-6532(02)00092-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

van der Heijden, J. T. M., and T. A. W. Splinter. "Aminoglutethimide-induced myelosuppression." Breast Cancer Research and Treatment 7, no. 3 (October 1986): 211–12. http://dx.doi.org/10.1007/bf01806252.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Maxwell, Mary B., and Karen E. Maher. "Chemotherapy-induced myelosuppression." Seminars in Oncology Nursing 8, no. 2 (May 1992): 113–23. http://dx.doi.org/10.1016/0749-2081(92)90027-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Sylvester, Robert K., Preston Steen, John M. Tate, Minesh Mehta, Ryan J. Petrich, Alexander Berg, and Jill Kolesar. "Temozolomide-induced severe myelosuppression." Anti-Cancer Drugs 22, no. 1 (January 2011): 104–10. http://dx.doi.org/10.1097/cad.0b013e3283407e9f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Green, Stephen L. "Linezolid and Reversible Myelosuppression." JAMA 285, no. 10 (March 14, 2001): 1291. http://dx.doi.org/10.1001/jama.285.10.1291.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Abena, P. A. "Linezolid and Reversible Myelosuppression." JAMA: The Journal of the American Medical Association 286, no. 16 (October 24, 2001): 1973–74. http://dx.doi.org/10.1001/jama.286.16.1973.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Javarappa, Komal K., Dimitrios Tsallos, and Caroline A. Heckman. "A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow." SLAS DISCOVERY: Advancing the Science of Drug Discovery 23, no. 7 (June 4, 2018): 687–96. http://dx.doi.org/10.1177/2472555218777968.

Full text

Abstract:

Myelosuppression is a major side effect of chemotherapy in cancer patients and can result in infections, bleeding complications, and increased risk of morbidity and mortality, as well as limit the drug dose and frequency of administration. Chemotherapy-induced myelosuppression is caused by the disruption of normal hematopoiesis. Thus, prior understanding of the adverse effects of chemotherapies on hematopoietic cells is essential to minimize the side effects of cancer treatment. Traditional methods such as colony-forming assays for studying chemotherapy-induced myelosuppression are time-consuming and labor intensive. High-throughput flow cytometry technologies and methods to detect rare hematopoietic cell populations are critical in advancing our understanding of how different blood cell types in complex biological samples respond to chemotherapeutic drugs. In the present study, hematopoietic progenitor cells were induced to differentiate into megakaryocytes and myeloid lineage cells. The expanded cells were then used in a multiplexed assay to monitor the dose-response effects of multiple chemotherapies on different stages of megakaryocyte differentiation and myeloid cell populations in a 96-well plate format. The assay offers an alternative method to evaluate the myelosuppressive potential of novel chemotherapeutic drugs compared to traditional lower throughput and labor-intensive assays.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Myelosuppression"

1

Stützer, Bianca. "Prävalenz latenter FeLV-Infektionen bei Katzen mit Myelosuppression oder Lymphom." Diss., lmu, 2010. http://nbn-resolving.de/urn:nbn:de:bvb:19-111585.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Quartino, Angelica L. "Pharmacometric Models for Improved Prediction of Myelosuppression and Treatment Response in Oncology." Doctoral thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-150431.

Full text

Abstract:

Chemotherapy plays an important role in the treatment of cancer. However, these drugs also cause death of non-malignant cells, resulting in severe side-effects. In addition, drug resistance may exist. Predictive tools for dose and drug selection are therefore warranted. In this thesis predictive pharmacometric models were developed for the main dose-limiting side-effect, neutropenia, and for treatment response following chemotherapy. Neutropenia is associated with a high risk for life-threatening infections and leads frequently to reduced dose delivery and thereby suboptimal treatment of the tumor. A better characterization of the dynamics of docetaxel induced neutropenia was obtained by simultaneous analysis of neutrophils and leukocytes. The fraction of neutrophils was shown to change over the time-course, hence leukocytes and neutrophil counts are not interchangeable biomarkers. Sometimes neutrophil count is reported as categorical severity of neutropenia (Grade 0-4). A method was developed that allowed analysis of these data closer to its true continuous nature. The main regulatory hormone of neutrophils is granulocyte colony stimulating factor (G-CSF). Although recombinant G-CSF is used as supportive therapy to prevent neutropenia, little is known of how the endogenous G-CSF concentrations vary in patients following chemotherapy. A prospective study was carried out and simultaneous analysis of endogenous G-CSF and neutrophils following chemotherapy enabled a more mechanistic model to be developed that also could verify the self-regulatory properties of the physiological system. Patient characteristics were investigated using a pharmacokinetic-myelosuppression model for docetaxel in patients with normal and impaired liver function. The model was a useful tool in evaluating different dosing strategies and a reduced dosing scheme was suggested in patients with poor liver function, thereby enabling docetaxel treatment in this patient population which has previously been excluded. Treatment of acute myeloid leukemia with daunorubicin and cytarabine is associated with drug resistance and high variability in pharmacokinetics, which was partly explained for daunorubicin by peripheral leukocyte count. An integrated model of the in vitro drug sensitivity and treatment response showed that in vitro drug sensitivity was predictive for treatment outcome in this patient population and may therefore be used for choice of drug. The developed pharmacometric models in this thesis may be useful in the optimization of treatments schedules for existing and new drugs as well as to assist in drug and dose selection to improve therapy in an individual patient. The models and methods presented may also facilitate pooled analysis of data and demonstrate principles which could be useful for the pharmacometric community.

APA, Harvard, Vancouver, ISO, and other styles

3

Patel, Nirav D., Kanishka Chakraborty, Garrett Messmer, Koyamangalath Krishnan, and John B. Bossaer. "Severe Sunitinib-Induced Myelosuppression in a Patient with a CYP 3A4 Polymorphism." Digital Commons @ East Tennessee State University, 2017. https://dc.etsu.edu/etsu-works/2330.

Full text

Abstract:

Sunitinib, an oral vascular endothelial growth factor receptor, is a first-line option for metastatic renal cell carcinoma and widely used in clinical practice. Despite the proven benefit of sunitnib in metastatic renal cell carcinoma, patients may suffer from a variety of adverse events including hypertension, fatigue, hypothyroidism, hand?foot skin reactions, rash, depigmentation, and myelosuppression. Myelosuppression is usually mild, transient and resolves during the two weeks at the end of each cycle where no drug is taken. We present a case of severe and early grade 3 neutropenia and thrombocytopenia occurring two weeks into a six-week cycle. Because of the extreme nature of the toxicity, CYP 3A4 polymorphisms were explored. The patient was found to be heterozygous for CYP 3A4*22, at least partially explaining the early-onset and severity of myelosuppression. This pharmacogenetics information resulted in a rechallenge of dose-reduced sunitinib, which was well tolerated by the patient. The current state of pharmacogenomics concerning sunitinb is also presented, and the need for greater research in this area is highlighted.

APA, Harvard, Vancouver, ISO, and other styles

4

Liu, Qing, and 刘晴. "Effect of Tian Xian Liquid on growth inhibition in colon cancer and moderation of 5-fluorouracil-induced myelosuppression." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2010. http://hub.hku.hk/bib/B45587188.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Xu, Zhibing. "Synthesis of Paclitaxel Analogs." Thesis, Virginia Tech, 2010. http://hdl.handle.net/10919/35376.

Full text

Abstract:

Paclitaxel is one of the most successful anti-cancer drugs, particularly in the treatment of breast cancer and ovarian cancer. For the investigation of the interaction between paclitaxel and MD-2 protein, and development of new antagonists for lipopolysaccharide, several C10 A-nor-paclitaxel analogs have been synthesized and their biological activities have been evaluated. In order to reduce the myelosuppression effect of the paclitaxel, several C3â ² and C4 paclitaxel analogs have been synthesized and their biological evaluation have been studied.
Master of Science

APA, Harvard, Vancouver, ISO, and other styles

6

Henningsson, Anja. "Mechanism-Based Pharmacokinetic and Pharmacodynamic Modelling of Paclitaxel." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5772.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

DeKoter, Rodney Peter. "Purification and partial characterization of a novel myelosuppressive factor from bone marrow." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1996. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/NQ42565.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Vong, Camille. "Model-Based Optimization of Clinical Trial Designs." Doctoral thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2014. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-233445.

Full text

Abstract:

General attrition rates in drug development pipeline have been recognized as a necessity to shift gears towards new methodologies that allow earlier and correct decisions, and the optimal use of all information accrued throughout the process. The quantitative science of pharmacometrics using pharmacokinetic-pharmacodynamic models was identified as one of the strategies core to this renaissance. Coupled with Optimal Design (OD), they constitute together an attractive toolkit to usher more rapidly and successfully new agents to marketing approval. The general aim of this thesis was to investigate how the use of novel pharmacometric methodologies can improve the design and analysis of clinical trials within drug development. The implementation of a Monte-Carlo Mapped power method permitted to rapidly generate multiple hypotheses and to adequately compute the corresponding sample size within 1% of the time usually necessary in more traditional model-based power assessment. Allowing statistical inference across all data available and the integration of mechanistic interpretation of the models, the performance of this new methodology in proof-of-concept and dose-finding trials highlighted the possibility to reduce drastically the number of healthy volunteers and patients exposed to experimental drugs. This thesis furthermore addressed the benefits of OD in planning trials with bio analytical limits and toxicity constraints, through the development of novel optimality criteria that foremost pinpoint information and safety aspects. The use of these methodologies showed better estimation properties and robustness for the ensuing data analysis and reduced the number of patients exposed to severe toxicity by 7-fold. Finally, predictive tools for maximum tolerated dose selection in Phase I oncology trials were explored for a combination therapy characterized by main dose-limiting hematological toxicity. In this example, Bayesian and model-based approaches provided the incentive to a paradigm change away from the traditional rule-based “3+3” design algorithm. Throughout this thesis several examples have shown the possibility of streamlining clinical trials with more model-based design and analysis supports. Ultimately, efficient use of the data can elevate the probability of a successful trial and increase paramount ethical conduct.

APA, Harvard, Vancouver, ISO, and other styles

9

Stützer, Bianca Veronica. "Prävalenz latenter FeLV-Infektionen bei Katzen mit Myelosuppression oder Lymphom." 2009. http://d-nb.info/1000917711/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

HUANG, CHO-CHIA, and 黃卓智. "Nephrotoxicity and Myelosuppression Induced by Cisplatin Administrations in Different Saline Concentrations in Dogs." Thesis, 2001. http://ndltd.ncl.edu.tw/handle/14335270281674366889.

Full text

Abstract:

碩士
國立屏東科技大學
獸醫學系
89
In order to compare the cisplatin-induced nephrotoxicity and myelosuppression in different saline concentration vehicles with multiple cisplatin administrations, eighteen apparently healthy-Beagle dogs were used dividing into 3 groups; Two of these groups were infused with 4 doses of cisplatin 70 mg/m2 which were distilled in 0.9% and 3.0% saline at 21 days intervals, respectively. And the control group was infused with 0.9% or 3.0% saline only. Based on results of the serum urea nitrogen, creatinine concentrations and clearance tests of creatinine, the 0.9% saline vehicle group showed less toxic to the kidneys comparing to the 3.0% saline vehicle group after receiving the third dose. From results of the urine concentration test and renal histopathological finding, the 0.9% saline-vehicle group also revealed less toxic to the renal tubules than the 3.0% saline-vehicle group after receiving four doses of cisplatin administration. Anemia was not evident in both of 0.9% and 3.0% saline-vehicle groups throughout the whole experiment. Transient and mild to moderate degree of neutropenia and thrombocytopenia was definitely found at the second week after each dose of cisplatin administration. Besides, there was no significant difference between 0.9% and 3.0% saline-vehicle groups in the rate and the level of onset and recovery of neutropenia and thrombocytopenia. According to the above results, we suggest 0.9% saline as the vehicle is more suitable than 3.0% one with multiple doses of cisplatin administration for dogs.

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Myelosuppression"

1

Champigneulle, Benoit, and Frédéric Pène. Pathophysiology and management of neutropenia in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0274.

Full text

Abstract:

Neutropenia is defined by an absolute neutrophil count <500 per mm3. Chemotherapy-induced myelosuppression represents the main mechanism accounting for neutropenia, although various bone marrow disorders might also result in impaired granulopoiesis. Neutropenia, especially when profound and prolonged, is a major risk factor for severe bacterial and fungal infections. Early initiation of empirical broad-spectrum antibiotic therapy represents the cornerstone of the treatment of febrile neutropenia. A number of infected neutropenic patients may exhibit organ failures, such as acute respiratory failures and/or severe sepsis requiring intensive care unit (ICU) admission. This chapter discusses the particularities in the management of neutropenic patients in the ICU, including outcome and criteria for ICU admission, management of antimicrobials with respect to the current epidemiological trends, and other measures specific to this subgroup of patients.

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Myelosuppression"

1

Zangemeister-Wittke, Uwe, and Hans-Uwe Simon. "Myelosuppression." In Encyclopedia of Cancer, 2437–40. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_3940.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gordon, Michael S. "Myelosuppression." In Current Cancer Therapeutics, 374–81. London: Current Medicine Group, 2001. http://dx.doi.org/10.1007/978-1-4613-1099-0_25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Dale, David C. "Myelosuppression." In Pathobiology of Cancer Regimen-Related Toxicities, 187–205. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-5438-0_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Zangemeister-Wittke, Uwe, and Hans-Uwe Simon. "Myelosuppression." In Encyclopedia of Cancer, 1–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_3940-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Zangemeister-Wittke, Uwe, and Hans-Uwe Simon. "Myelosuppression." In Encyclopedia of Cancer, 2989–93. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-662-46875-3_3940.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Rodriguez Cruz, Nidra I., Renee M. Madden, and Craig A. Mullen. "Supportive Care: Myelosuppression." In Pediatric Oncology, 208–17. Boston, MA: Springer US, 2005. http://dx.doi.org/10.1007/978-0-387-24472-3_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Dygai, A. M., and V. V. Zhdanov. "Alterations in Blood System Induced By Extreme Conditions Provoking No Myelosuppression." In Theory of Hematopoiesis Control, 15–25. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-08584-5_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Hofer, M., and M. Pospíšil. "Clinically Available Drugs as Potential Curative Means for Treatment of Radiation-Induced Myelosuppression." In Fundamentals for the Assessment of Risks from Environmental Radiation, 421–26. Dordrecht: Springer Netherlands, 1999. http://dx.doi.org/10.1007/978-94-011-4585-5_54.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Dygai, A. M., and V. V. Zhdanov. "Alterations in the Blood System During Myelosuppression Induced by Cytostatic and Radiation Treatment." In Theory of Hematopoiesis Control, 33–46. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-08584-5_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Farese, Ann M., Melanie V. Cohen, and Thomas J. MacVittie. "Recombinant Human G-CSF Enhances Recovery and Improves Survival from Severe Radiation-Induced Myelosuppression." In Twenty Years of G-CSF, 365–80. Basel: Springer Basel, 2011. http://dx.doi.org/10.1007/978-3-0348-0218-5_19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Myelosuppression"

1

Ditto, Andrew J., Nikki K. Robbishaw, Matthew J. Panzner, Wiley J. Youngs, and Yang H. Yun. "Targeting Ovarian Cancer Cells With Rapidly Biodegradable L-Tyrosine Polyphosphate Nanoparticles Decorated With Folate." In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53138.

Full text

Abstract:

Chemotherapy employs toxic chemicals to kill rapidly dividing cells. Examples of FDA approved antineoplastic drugs include cisplatin, doxorubicin, and paclitaxel. Since most of these drugs are nonspecific, they also damage normal tissues as well as the aberrant tumors. As a result, non-specific therapies have multiple side effects, which include myelosuppression, mucositis, alopecia, nephrotoxicity, and genotoxcity. In order to minimize these issues, researchers have begun to conjugate antineoplastic chemicals with targeting moieties or encapsulate drugs into nanoparticles decorated with compounds, peptides, or proteins that recognize specific cellular receptors, which are upregulated by the neoplastic cells. The targeting moieties aid in the accumulation of these drugs within the blood vessels of carcinomas, while keeping concentrations low in the systemic circulation. Thus, targeted delivery systems are able to minimize the unwanted side effects and increase the efficacy of chemotherapies.

APA, Harvard, Vancouver, ISO, and other styles

2

Watson, Rebecca, and Suliman Al-Fayoumi. "Abstract 2602: The nonclinical toxicology profile of pacritinib, a JAK2/FLT3 inhibitor with no dose-limiting clinical myelosuppression." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-2602.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Baerlocher, Gabriela M., Joshua Rusbuldt, Fei Huang, and Jacqueline Bussolari. "Abstract 2732: Myelosuppression in patients treated with the telomerase inhibitor imetelstat is not mediated through activation of toll-like receptors." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-2732.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Wei, X.-N., D.-H. Zheng, Y.-Q. Mo, J.-D. Ma, Y.-L. Chen, and L. Dai. "THU0201 Older age, hypoalbuminaemia and renal failure might be poor prognosis factors for low dose methotrexate-induced myelosuppression in patients with rheumatoid arthritis." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.3723.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Fisusi, Funmilola Adesodun, Omotunde Okubanjo, Kar Wai Chooi, Andreas G. Schatzlein, and Ijeoma F. Uchegbu. "Abstract 5530: Chitosan amphiphile nanoparticles reduced the myelosuppressive effects of lomustine." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-5530.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Blaes, AH, V. Chia, C. Solid, J. Page, RL Barron, MR Choi, and TJ Arneson. "Abstract P1-15-01: Patterns of granulocyte colony stimulating factor (G-CSF) use in elderly breast cancer (BC) patients receiving myelosuppressive chemotherapy." In Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/0008-5472.sabcs12-p1-15-01.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Schwartzberg, L., G. Bhat, K. Mezei, I. Lang, YW Moon, L. Senviratne, S. Chawla, P. Cobb, and Z. Yang. "Abstract P1-13-05: Efficacy and safety of eflapegrastim confirmed in reducing severe neutropenia in breast cancer patients treated with myelosuppressive chemotherapy in the second Phase 3 randomized controlled multinational trial compared to pegfilgrastim (RECOVER trial)." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p1-13-05.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Myelosuppression"

1

Yang, Sihang, Hong Che, Li Xiao, Bingjie Zhao, and Songshan Liu. Traditional Chinese medicine on treating myelosuppression after chemotherapy A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2020. http://dx.doi.org/10.37766/inplasy2020.12.0097.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Jiang, Jiangwang, Huaiyu Li, Renliang Li, Qianjie Qiu, Baoguo Chen, and Zhiming Li. Efficacy and safety of Chinese Herbal Medicine for Myelosuppression after platinum-based chemotherapy: A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2020. http://dx.doi.org/10.37766/inplasy2020.11.0116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!